{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:22:04Z","timestamp":1791901324406,"version":"4.3.4"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41584-025-01252-7","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T10:51:01Z","timestamp":1746528661000},"page":"355-369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Arterial and venous thrombosis in systemic and monogenic vasculitis"],"prefix":"10.1038","volume":"21","author":[{"given":"Federica","family":"Bello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-0774","authenticated-orcid":false,"given":"Filippo","family":"Fagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Bagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8289-4922","authenticated-orcid":false,"given":"Catherine L.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7169-6936","authenticated-orcid":false,"given":"Aladdin J.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emire","family":"Seyahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-8321","authenticated-orcid":false,"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"1252_CR1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","volume":"18","author":"K Stark","year":"2021","unstructured":"Stark, K. & Massberg, S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat. Rev. Cardiol. 18, 666\u2013682 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"1252_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1160\/TH12-08-0634","volume":"109","author":"CT Esmon","year":"2013","unstructured":"Esmon, C. T. Molecular circuits in thrombosis and inflammation. Thromb. Haemost. 109, 416\u2013420 (2013).","journal-title":"Thromb. Haemost."},{"key":"1252_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","volume":"13","author":"B Engelmann","year":"2012","unstructured":"Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34\u201345 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1252_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-022-00335-z","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana, A. A. et al. Cancer-associated venous thromboembolism. Nat. Rev. Dis. Prim. 8, 1\u201318 (2022).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1252_CR5","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1161\/ATVBAHA.120.314514","volume":"40","author":"N Mackman","year":"2020","unstructured":"Mackman, N. et al. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses. Arterioscler. Thromb. Vasc. Biol. 40, 2033\u20132044 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1252_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nri2402","volume":"8","author":"D Rittirsch","year":"2008","unstructured":"Rittirsch, D., Flierl, M. A. & Ward, P. A. Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 8, 776\u2013787 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1252_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12959-015-0047-z","volume":"13","author":"G Emmi","year":"2015","unstructured":"Emmi, G. et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb. J. 13, 15 (2015).","journal-title":"Thromb. J."},{"key":"1252_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/ncprheum0092","volume":"2","author":"Y Sherer","year":"2006","unstructured":"Sherer, Y. & Shoenfeld, Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 2, 99\u2013106 (2006).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"1252_CR9","first-page":"S94","volume":"26","author":"R Phillip","year":"2008","unstructured":"Phillip R., Luqmani, R. Mortality in systemic vasculitis: a systematic review. Clin. Exp. Rheumatol. 26, S94\u2013104 (2008).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1252_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/s-2003-44555","volume":"29","author":"A Della Rossa","year":"2003","unstructured":"Della Rossa, A., Tavoni, A. & Bombardieri, S. Hyperviscosity syndrome in cryoglobulinemia: clinical aspects and therapeutic considerations. Semin. Thromb. Hemost. 29, 473\u2013477 (2003).","journal-title":"Semin. Thromb. Hemost."},{"key":"1252_CR11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1046\/j.1442-200x.2000.01270.x","volume":"42","author":"Y Kuramochi","year":"2000","unstructured":"Kuramochi, Y. et al. Hemodynamic factors of thrombus formation in coronary aneurysms associated with Kawasaki disease. Pediatrics Int. 42, 470\u2013475 (2000).","journal-title":"Pediatrics Int."},{"key":"1252_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10067-020-05166-5","volume":"40","author":"L Du","year":"2021","unstructured":"Du, L. et al. Multisystemic manifestations of IgA vasculitis. Clin. Rheumatol. 40, 43\u201352 (2021).","journal-title":"Clin. Rheumatol."},{"key":"1252_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching, A. R. et al. ANCA-associated vasculitis. Nat. Rev. Dis. Prim. 6, 71 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1252_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002949","volume":"9","author":"J Rathmann","year":"2023","unstructured":"Rathmann, J. et al. Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study. RMD Open\u00a09, e002949 (2023).","journal-title":"RMD Open"},{"key":"1252_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich, B. et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann. Rheum. Dis. 83, 30\u201347 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1252_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3899\/jrheum.220851","volume":"50","author":"S Moiseev","year":"2023","unstructured":"Moiseev, S. et al. Traditional and disease-specific risk factors for cardiovascular events in antineutrophil cytoplasmic antibody-associated vasculitis: a multinational retrospective study. J. Rheumatol. 50, 1145\u20131151 (2023).","journal-title":"J. Rheumatol."},{"key":"1252_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3899\/jrheum.160249","volume":"44","author":"AJ Mohammad","year":"2017","unstructured":"Mohammad, A. J. et al. Rate of comorbidities in giant cell arteritis: a population-based study. J. Rheumatol. 44, 84\u201390 (2017).","journal-title":"J. Rheumatol."},{"issue":"Suppl 3","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"iii79","DOI":"10.1093\/rheumatology\/kez617","volume":"59","author":"A Kronbichler","year":"2020","unstructured":"Kronbichler, A. et al. Comorbidities in ANCA-associated vasculitis. Rheumatology 59 (Suppl. 3), iii79\u2013iii83 (2020).","journal-title":"Rheumatology"},{"key":"1252_CR19","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/ndt\/gfac320","volume":"38","author":"B S\u00e1nchez \u00c1lamo","year":"2023","unstructured":"S\u00e1nchez \u00c1lamo, B. et al. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 38, 1655\u20131665 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1252_CR20","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","volume":"76","author":"JA Tan","year":"2017","unstructured":"Tan, J. A. et al. Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann. Rheum. Dis. 76, 1566\u20131574 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1252_CR21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488\u2013494 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1252_CR22","doi-asserted-by":"publisher","first-page":"2004158","DOI":"10.1183\/13993003.04158-2020","volume":"57","author":"A Bettiol","year":"2021","unstructured":"Bettiol, A. et al. Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome). Eur. Respir. J. 57, 2004158 (2021).","journal-title":"Eur. Respir. J."},{"key":"1252_CR23","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/ard.2008.099051","volume":"68","author":"Y Allenbach","year":"2009","unstructured":"Allenbach, Y. et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener\u2019s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann. Rheum. Dis. 68, 564\u2013567 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1252_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2021.03.032","volume":"325","author":"AH Clifford","year":"2021","unstructured":"Clifford, A. H. & Cohen Tervaert, J. W. Cardiovascular events and the role of accelerated atherosclerosis in systemic vasculitis. Atherosclerosis 325, 8\u201315 (2021).","journal-title":"Atherosclerosis"},{"key":"1252_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.semnephrol.2016.05.006","volume":"36","author":"AS Go","year":"2016","unstructured":"Go, A. S. Cardiovascular disease consequences of CKD. Semin. Nephrol. 36, 293\u2013304 (2016).","journal-title":"Semin. Nephrol."},{"key":"1252_CR26","first-page":"248","volume":"32","author":"S Moiseev","year":"2017","unstructured":"Moiseev, S. et al. End-stage renal disease in ANCA-associated vasculitis. Nephrol. Dial. Transplant. 32, 248\u2013253 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1252_CR27","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1093\/rheumatology\/keab057","volume":"60","author":"M Liapi","year":"2021","unstructured":"Liapi, M. et al. Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study. Rheumatology 60, 4616\u20134623 (2021).","journal-title":"Rheumatology"},{"key":"1252_CR28","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1093\/rheumatology\/keac669","volume":"62","author":"D Tabakovic","year":"2023","unstructured":"Tabakovic, D. et al. High risk of stroke in ANCA-associated vasculitis-a population-based study. Rheumatology 62, 2806\u20132812 (2023).","journal-title":"Rheumatology"},{"key":"1252_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/phar.2663","volume":"42","author":"AL Armbruster","year":"2022","unstructured":"Armbruster, A. L. et al. The role of inflammation in the pathogenesis and treatment of arrhythmias. Pharmacotherapy 42, 250\u2013262 (2022).","journal-title":"Pharmacotherapy"},{"key":"1252_CR30","doi-asserted-by":"publisher","first-page":"105540","DOI":"10.1016\/j.jbspin.2023.105540","volume":"90","author":"Y Vegting","year":"2023","unstructured":"Vegting, Y. et al. Traditional and disease-related cardiovascular risk factors in ANCA-associated vasculitis: a prospective, two-centre cohort study. Joint Bone Spine 90, 105540 (2023).","journal-title":"Joint Bone Spine"},{"key":"1252_CR31","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1093\/rheumatology\/keab071","volume":"60","author":"S Moiseev","year":"2021","unstructured":"Moiseev, S. et al. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology 60, 4654\u20134661 (2021).","journal-title":"Rheumatology"},{"key":"1252_CR32","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1182\/bloodadvances.2023011937","volume":"8","author":"MH Busch","year":"2024","unstructured":"Busch, M. H. et al. The intrinsic coagulation pathway plays a dominant role in driving hypercoagulability in ANCA-associated vasculitis. Blood Adv. 8, 1295\u20131304 (2024).","journal-title":"Blood Adv."},{"issue":"SI2","key":"1252_CR33","doi-asserted-by":"publisher","first-page":"SI228","DOI":"10.1093\/rheumatology\/kead600","volume":"63","author":"E Go","year":"2024","unstructured":"Go, E. et al. Von Willebrand factor antigen as a marker of disease activity in childhood-onset antineutrophil cytoplasmic antibody\u2013associated vasculitis. Rheumatology 63 (SI2), SI228\u2013SI232 (2024).","journal-title":"Rheumatology"},{"key":"1252_CR34","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/j.1538-7836.2010.04034.x","volume":"8","author":"B van Zaane","year":"2010","unstructured":"van Zaane, B. et al. Systematic review on the effect of glucocorticoid use on procoagulant, anti\u2010coagulant and fibrinolytic factors. J. Thromb. Haemost. 8, 2483\u20132493 (2010).","journal-title":"J. Thromb. Haemost."},{"key":"1252_CR35","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/rheumatology\/keab514","volume":"61","author":"S Sartorelli","year":"2022","unstructured":"Sartorelli, S. et al. Revisiting characteristics, treatment and outcome of cardiomyopathy in eosinophilic granulomatosis with polyangiitis (formerly Churg\u2013Strauss). Rheumatology 61, 1175\u20131184 (2022).","journal-title":"Rheumatology"},{"key":"1252_CR36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejim.2020.12.008","volume":"85","author":"M Zampieri","year":"2021","unstructured":"Zampieri, M. et al. Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg\u2013Strauss syndrome): prospective evaluation at a tertiary referral centre. Eur. J. Intern. Med. 85, 68\u201379 (2021).","journal-title":"Eur. J. Intern. Med."},{"key":"1252_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11926-022-01087-1","volume":"24","author":"M Bond","year":"2022","unstructured":"Bond, M. et al. At the heart of eosinophilic granulomatosis with polyangiitis: into cardiac and vascular involvement. Curr. Rheumatol. Rep. 24, 337\u2013351 (2022).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1252_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-020-00948-x","volume":"22","author":"R Watanabe","year":"2020","unstructured":"Watanabe, R. et al. Pathogenesis of giant cell arteritis and Takayasu arteritis \u2014 similarities and differences. Curr. Rheumatol. Rep. 22, 1\u201311 (2020).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1252_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41572-021-00327-5","volume":"7","author":"D Pugh","year":"2022","unstructured":"Pugh, D. et al. Large-vessel vasculitis. Nat. Rev. Dis. Prim. 7, 93 (2022).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1252_CR40","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder, G. G. et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 33, 1122\u20131128 (1990).","journal-title":"Arthritis Rheum."},{"key":"1252_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaut.2014.01.012","volume":"48\u201349","author":"AWS De Souza","year":"2014","unstructured":"De Souza, A. W. S. & de Carvalho, J. F. Diagnostic and classification criteria of Takayasu arteritis. J. Autoimmun. 48\u201349, 79\u201383 (2014).","journal-title":"J. Autoimmun."},{"key":"1252_CR42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/art.21075","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani, C. et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 53, 293\u2013297 (2005).","journal-title":"Arthritis Rheum."},{"key":"1252_CR43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/MD.0b013e3181af4518","volume":"88","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay, M. A. et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine 88, 227\u2013235 (2009).","journal-title":"Medicine"},{"key":"1252_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/jnnp-2014-307614","volume":"86","author":"M Samson","year":"2015","unstructured":"Samson, M. et al. Stroke associated with giant cell arteritis: a population-based study. J. Neurol. Neurosurg. Psychiatry 86, 216\u2013221 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1252_CR45","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","volume":"48","author":"C Salvarani","year":"2009","unstructured":"Salvarani, C. et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology 48, 250\u2013253 (2009).","journal-title":"Rheumatology"},{"key":"1252_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-023-03091-x","volume":"25","author":"T Penet","year":"2023","unstructured":"Penet, T. et al. Giant cell arteritis-related cerebrovascular ischemic events: a French retrospective study of 271 patients, systematic review of the literature and meta-analysis. Arthritis Res. Ther. 25, 1\u201313 (2023).","journal-title":"Arthritis Res. Ther."},{"key":"1252_CR47","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/01.md.0000145369.25558.b5","volume":"83","author":"MA Gonzalez-Gay","year":"2004","unstructured":"Gonzalez-Gay, M. A. et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine 83, 342\u2013347 (2004).","journal-title":"Medicine"},{"key":"1252_CR48","first-page":"506","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco, C. et al. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology 56, 506\u2013515 (2017).","journal-title":"Rheumatology"},{"key":"1252_CR49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/03009742.2011.641581","volume":"41","author":"M Czihal","year":"2012","unstructured":"Czihal, M. et al. Sonographic and clinical pattern of extracranial and cranial giant cell arteritis. Scand. J. Rheumatol. 41, 231\u2013236 (2012).","journal-title":"Scand. J. Rheumatol."},{"key":"1252_CR50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/annrheumdis-2013-204113","volume":"74","author":"JC Robson","year":"2015","unstructured":"Robson, J. C. et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann. Rheum. Dis. 74, 129\u2013135 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1252_CR51","doi-asserted-by":"publisher","first-page":"502","DOI":"10.7326\/0003-4819-122-7-199504010-00004","volume":"122","author":"JM Evans","year":"1995","unstructured":"Evans, J. M., O\u2019Fallon, W. M. & Hunder, G. G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann. Intern. Med. 122, 502\u2013507 (1995).","journal-title":"Ann. Intern. Med."},{"issue":"Suppl(S2)","key":"1252_CR52","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1016\/S0167-5273(96)02813-6","volume":"54","author":"A Hata","year":"1996","unstructured":"Hata, A. et al. Angiographic findings of Takayasu arteritis: new classification. Int. J. Cardiol. 54 (Suppl(S2)), S155\u2013S163 (1996).","journal-title":"Int. J. Cardiol."},{"key":"1252_CR53","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.3899\/jrheum.150097","volume":"42","author":"L Yang","year":"2015","unstructured":"Yang, L. et al. Clinical features and outcomes of Takayasu arteritis with neurological symptoms in China: a retrospective study. J. Rheumatol. 42, 1846\u20131852 (2015).","journal-title":"J. Rheumatol."},{"key":"1252_CR54","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1445-2197.2005.03312.x","volume":"75","author":"BP Mwipatayi","year":"2005","unstructured":"Mwipatayi, B. P. et al. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J. Surg. 75, 110\u2013117 (2005).","journal-title":"ANZ J. Surg."},{"key":"1252_CR55","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1161\/CIRCULATIONAHA.116.027094","volume":"136","author":"C Comarmond","year":"2017","unstructured":"Comarmond, C. et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation 136, 1114\u20131122 (2017).","journal-title":"Circulation"},{"key":"1252_CR56","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.semarthrit.2017.11.001","volume":"47","author":"H Kim","year":"2018","unstructured":"Kim, H. & Barra, L. Ischemic complications in Takayasu\u2019s arteritis: a meta-analysis. Semin. Arthritis Rheum. 47, 900\u2013906 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"1252_CR57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.avsg.2016.02.011","volume":"35","author":"R Serra","year":"2016","unstructured":"Serra, R. et al. Updates in pathophysiology, diagnosis and management of Takayasu arteritis. Ann. Vasc. Surg. 35, 210\u2013225 (2016).","journal-title":"Ann. Vasc. Surg."},{"key":"1252_CR58","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.kint.2017.06.027","volume":"93","author":"Z Chen","year":"2018","unstructured":"Chen, Z. et al. The renal artery is involved in Chinese Takayasu\u2019s arteritis patients. Kidney Int. 93, 245\u2013251 (2018).","journal-title":"Kidney Int."},{"key":"1252_CR59","first-page":"636","volume":"43","author":"S Uysal","year":"2025","unstructured":"Uysal, S. et al. Carotid artery ultrasonography and shear wave elastography in Takayasu\u2019s arteritis: a comparative analysis with diabetes mellitus. Clin. Exp. Rheumatol. 43, 636\u2013646 (2025).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1252_CR60","doi-asserted-by":"publisher","first-page":"152199","DOI":"10.1016\/j.semarthrit.2023.152199","volume":"60","author":"AK Ucar","year":"2023","unstructured":"Ucar, A. K. et al. Increased arterial stiffness and accelerated atherosclerosis in Takayasu arteritis. Semin. Arthritis Rheum. 60, 152199 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1252_CR61","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.semarthrit.2012.11.001","volume":"43","author":"E Seyahi","year":"2013","unstructured":"Seyahi, E. et al. Aortic and coronary calcifications in Takayasu arteritis. Semin. Arthritis Rheum. 43, 96\u2013104 (2013).","journal-title":"Semin. Arthritis Rheum."},{"key":"1252_CR62","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1161\/STROKEAHA.121.034445","volume":"53","author":"A Mirouse","year":"2022","unstructured":"Mirouse, A. et al. Cerebrovascular ischemic events in patients with Takayasu arteritis. Stroke 53, 1550\u20131557 (2022).","journal-title":"Stroke"},{"key":"1252_CR63","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.12.005","volume":"25","author":"MM Duarte","year":"2016","unstructured":"Duarte, M. M. et al. Stroke and transient ischemic attack in Takayasu\u2019s arteritis: a systematic review and meta-analysis. J. Stroke Cerebrovasc. Dis. 25, 781\u2013791 (2016).","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"1252_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3988\/jcn.2012.8.2.109","volume":"8","author":"J Hwang","year":"2012","unstructured":"Hwang, J. et al. Ischemic stroke in Takayasu\u2019s arteritis: lesion patterns and possible mechanisms. J. Clin. Neurol. 8, 109\u2013115 (2012).","journal-title":"J. Clin. Neurol."},{"key":"1252_CR65","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/annrheumdis-2014-205665","volume":"75","author":"JA Avi\u00f1a-Zubieta","year":"2016","unstructured":"Avi\u00f1a-Zubieta, J. A. et al. The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study. Ann. Rheum. Dis. 75, 148\u2013154 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1252_CR66","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/joim.13446","volume":"291","author":"D Michailidou","year":"2022","unstructured":"Michailidou, D. et al. Risk of venous and arterial thromboembolism in patients with giant cell arteritis and\/or polymyalgia rheumatica: a Veterans Health Administration population-based study in the United States. J. Intern. Med. 291, 665\u2013675 (2022).","journal-title":"J. Intern. Med."},{"key":"1252_CR67","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jbspin.2016.04.011","volume":"84","author":"KH Ly","year":"2017","unstructured":"Ly, K. H. et al. Venous thrombosis in patients with giant cell arteritis: features and outcomes in a cohort study. Joint Bone Spine 84, 323\u2013326 (2017).","journal-title":"Joint Bone Spine"},{"key":"1252_CR68","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/art.39847","volume":"69","author":"S Unizony","year":"2017","unstructured":"Unizony, S. et al. Temporal trends of venous thromboembolism risk before and after diagnosis of giant cell arteritis. Arthritis Rheumatol. 69, 176\u2013184 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1252_CR69","doi-asserted-by":"publisher","first-page":"997347","DOI":"10.3389\/fimmu.2022.997347","volume":"13","author":"D Michailidou","year":"2022","unstructured":"Michailidou, D. et al. Predictive models for thromboembolic events in giant cell arteritis: a US veterans health administration population-based study. Front. Immunol. 13, 997347 (2022).","journal-title":"Front. Immunol."},{"key":"1252_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-00234-1","volume":"7","author":"Y Yazici","year":"2021","unstructured":"Yazici, Y. et al. Beh\u00e7et syndrome. Nat. Rev. Dis. Prim. 7, 1\u201314 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1252_CR71","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","volume":"403","author":"G Emmi","year":"2024","unstructured":"Emmi, G. et al. Beh\u00e7et\u2019s syndrome. Lancet 403, 1093\u20131108 (2024).","journal-title":"Lancet"},{"key":"1252_CR72","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/03009742.2021.1904622","volume":"51","author":"M Torgutalp","year":"2022","unstructured":"Torgutalp, M. et al. Patient characteristics in Beh\u00e7et\u2019s Syndrome and their associations with major organ involvement: a single-centre experience of 2118 cases. Scand. J. Rheumatol. 51, 50\u201358 (2022).","journal-title":"Scand. J. Rheumatol."},{"issue":"4 Suppl. 67","key":"1252_CR73","first-page":"S47","volume":"29","author":"H Ideguchi","year":"2011","unstructured":"Ideguchi, H. et al. Characteristics of vascular involvement in Beh\u00e7et\u2019s disease in Japan: a retrospective cohort study. Clin. Exp. Rheumatol. 29 (4 Suppl. 67), S47\u2013S53 (2011).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1252_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/MD.0b013e3182428126","volume":"91","author":"D Saadoun","year":"2012","unstructured":"Saadoun, D. et al. Long-term outcome of arterial lesions in Beh\u00e7et disease: a series of 101 patients. Medicine 91, 18\u201324 (2012).","journal-title":"Medicine"},{"key":"1252_CR75","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/rheumatology\/keu233","volume":"53","author":"K Tascilar","year":"2014","unstructured":"Tascilar, K. et al. Vascular involvement in Beh\u00e7et\u2019s syndrome: a retrospective analysis of associations and the time course. Rheumatology 53, 2018\u20132021 (2014).","journal-title":"Rheumatology"},{"key":"1252_CR76","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/rheumatology\/kez352","volume":"59","author":"Y Ozguler","year":"2020","unstructured":"Ozguler, Y. et al. Clinical course of acute deep vein thrombosis of the legs in Beh\u00e7et\u2019s syndrome. Rheumatology 59, 799\u2013806 (2020).","journal-title":"Rheumatology"},{"key":"1252_CR77","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s10067-013-2205-7","volume":"32","author":"Y Fei","year":"2013","unstructured":"Fei, Y. et al. Major vascular involvement in Beh\u00e7et\u2019s disease: a retrospective study of 796 patients. Clin. Rheumatol. 32, 845\u2013852 (2013).","journal-title":"Clin. Rheumatol."},{"key":"1252_CR78","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","volume":"19","author":"A Bettiol","year":"2022","unstructured":"Bettiol, A. et al. Vascular Beh\u00e7et syndrome: from pathogenesis to treatment. Nat. Rev. Rheumatol. 19, 111\u2013126 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1252_CR79","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MD.0b013e318242ff37","volume":"91","author":"E Seyahi","year":"2012","unstructured":"Seyahi, E. et al. Pulmonary artery involvement and associated lung disease in Beh\u00e7et disease: a series of 47 patients. Medicine 91, 35\u201348 (2012).","journal-title":"Medicine"},{"key":"1252_CR80","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1007\/s10067-021-05958-3","volume":"40","author":"S Sanduleanu","year":"2021","unstructured":"Sanduleanu, S. & Jansen, T. L. T. A. Hughes\u2013Stovin syndrome (HSS): current status and future perspectives. Clin. Rheumatol. 40, 4787\u20134789 (2021).","journal-title":"Clin. Rheumatol."},{"key":"1252_CR81","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","volume":"14","author":"H Yazici","year":"2018","unstructured":"Yazici, H. et al. Beh\u00e7et syndrome: a contemporary view. Nat. Rev. Rheumatol. 14, 107\u2013119 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1252_CR82","first-page":"2021","volume":"42","author":"B Ordu","year":"2024","unstructured":"Ordu, B. et al. Pulmonary artery involvement due to Beh\u00e7et\u2019s syndrome and Hughes Stovin syndrome: a comparative study. Clin. Exp. Rheumatol. 42, 2021\u20132031 (2024).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1252_CR83","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10067-022-06423-5","volume":"42","author":"R Y\u0131ld\u0131r\u0131m","year":"2023","unstructured":"Y\u0131ld\u0131r\u0131m, R. et al. Scoping beyond pulmonary artery involvement; pulmonary involvement in Behcet\u2019s disease; a retrospective analysis of 28 patients. Clin. Rheumatol. 42, 849\u2013853 (2023).","journal-title":"Clin. Rheumatol."},{"key":"1252_CR84","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.semtcvs.2018.07.008","volume":"30","author":"H Tuzun","year":"2018","unstructured":"Tuzun, H. et al. Surgical treatment of pulmonary complications in Beh\u00e7et\u2019s syndrome. Semin. Thorac. Cardiovasc. Surg. 30, 369\u2013378 (2018).","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"1252_CR85","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1055\/s-0037-1604411","volume":"66","author":"\u015eO Ylldlzeli","year":"2018","unstructured":"Ylldlzeli, \u015e. O. et al. Outcomes of patients with Beh\u00e7et\u2019s syndrome after pulmonary endarterectomy. Thorac. Cardiovasc. Surg. 66, 187\u2013192 (2018).","journal-title":"Thorac. Cardiovasc. Surg."},{"key":"1252_CR86","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jvs.2011.07.049","volume":"55","author":"H Tuzun","year":"2012","unstructured":"Tuzun, H. et al. Management and prognosis of nonpulmonary large arterial disease in patients with Beh\u00e7et disease. J. Vasc. Surg. 55, 157\u2013163 (2012).","journal-title":"J. Vasc. Surg."},{"key":"1252_CR87","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MD.0b013e3182428f49","volume":"91","author":"G Geri","year":"2012","unstructured":"Geri, G. et al. Spectrum of cardiac lesions in Beh\u00e7et disease: a series of 52 patients and review of the literature. Medicine 91, 25\u201334 (2012).","journal-title":"Medicine"},{"key":"1252_CR88","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000494","volume":"94","author":"F Alibaz-Oner","year":"2015","unstructured":"Alibaz-Oner, F. et al. Beh\u00e7et disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine 94, e494 (2015).","journal-title":"Medicine"},{"key":"1252_CR89","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jvsv.2021.02.007","volume":"9","author":"A Aksoy","year":"2021","unstructured":"Aksoy, A. et al. Predictors for the risk and severity of post-thrombotic syndrome in vascular Beh\u00e7et\u2019s disease. J. Vasc. Surg. Venous Lymphat. Disord. 9, 1451\u20131459 (2021).","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"1252_CR90","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.berh.2016.08.002","volume":"30","author":"E Seyahi","year":"2016","unstructured":"Seyahi, E. Beh\u00e7et\u2019s disease: how to diagnose and treat vascular involvement. Best Pract. Res. Clin. Rheumatol. 30, 279\u2013295 (2016).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"1252_CR91","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.semarthrit.2014.10.014","volume":"44","author":"E Seyahi","year":"2015","unstructured":"Seyahi, E. et al. An outcome survey of 43 patients with Budd-Chiari syndrome due to Beh\u00e7et\u2019s syndrome followed up at a single, dedicated center. Semin. Arthritis Rheum. 44, 602\u2013609 (2015).","journal-title":"Semin. Arthritis Rheum."},{"key":"1252_CR92","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.clinre.2019.10.006","volume":"44","author":"MA Sakr","year":"2020","unstructured":"Sakr, M. A. et al. Characteristics and outcome of primary Budd\u2013Chiari syndrome due to Beh\u00e7et\u2019s syndrome. Clin. Res. Hepatol. Gastroenterol. 44, 503\u2013512 (2020).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"1252_CR93","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1212\/WNL.0b013e318238edeb","volume":"77","author":"D Uluduz","year":"2011","unstructured":"Uluduz, D. et al. Clinical characteristics of pediatric-onset neuro-Beh\u00e7et disease. Neurology 77, 1900\u20131905 (2011).","journal-title":"Neurology"},{"key":"1252_CR94","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s00415-009-5088-4","volume":"256","author":"N Yesilot","year":"2009","unstructured":"Yesilot, N. et al. Cerebral venous thrombosis in Beh\u00e7et\u2019s disease compared to those associated with other etiologies. J. Neurol. 256, 1134\u20131142 (2009).","journal-title":"J. Neurol."},{"key":"1252_CR95","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jvsv.2018.11.006","volume":"7","author":"E Seyahi","year":"2019","unstructured":"Seyahi, E. et al. Increased vein wall thickness in Beh\u00e7et disease. J. Vasc. Surg. Venous Lymphat. Disord. 7, 677\u2013684.e2 (2019).","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"1252_CR96","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/rheumatology\/keaa264","volume":"60","author":"F Alibaz-Oner","year":"2021","unstructured":"Alibaz-Oner, F. et al. Femoral vein wall thickness measurement: a new diagnostic tool for Beh\u00e7et\u2019s disease. Rheumatology 60, 288\u2013296 (2021).","journal-title":"Rheumatology"},{"key":"1252_CR97","doi-asserted-by":"publisher","first-page":"152246","DOI":"10.1016\/j.semarthrit.2023.152246","volume":"62","author":"H Karadeniz","year":"2023","unstructured":"Karadeniz, H. et al. Diffuse generalized venulitis as the primary pathology of Beh\u00e7et\u2019s disease: a comprehensive magnetic resonance venography study. Semin. Arthritis Rheum. 62, 152246 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1252_CR98","first-page":"2032","volume":"42","author":"SAC Neaime","year":"2024","unstructured":"Neaime, S. A. C. et al. Evaluation of common femoral vein thickness as a diagnostic tool for Beh\u00e7et\u2019s disease in a non-endemic area. Clin. Exp. Rheumatol. 42, 2032\u20132039 (2024).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1252_CR99","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/rheumatology\/keh542","volume":"44","author":"CD Buckley","year":"2005","unstructured":"Buckley, C. D. et al. Endothelial cells, fibroblasts and vasculitis. Rheumatology 44, 860 (2005).","journal-title":"Rheumatology"},{"key":"1252_CR100","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1681\/ASN.2012020119","volume":"23","author":"L Halbwachs","year":"2012","unstructured":"Halbwachs, L. & Lesavre, P. Endothelium-neutrophil interactions in ANCA-associated diseases. J. Am. Soc. Nephrol. 23, 1449\u20131461 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1252_CR101","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0002-9440(10)62952-5","volume":"167","author":"D Huugen","year":"2005","unstructured":"Huugen, D. et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-\u03b1. Am. J. Pathol. 167, 47 (2005).","journal-title":"Am. J. Pathol."},{"key":"1252_CR102","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","volume":"15","author":"D Nakazawa","year":"2018","unstructured":"Nakazawa, D. et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat. Rev. Rheumatol. 15, 91\u2013101 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1252_CR103","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1182\/blood.V96.8.2822","volume":"96","author":"C Hess","year":"2000","unstructured":"Hess, C., Sadallah, S. & Schifferli, J. A. Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood 96, 2822\u20132827 (2000).","journal-title":"Blood"},{"key":"1252_CR104","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.kint.2018.01.013","volume":"94","author":"T Kraaij","year":"2018","unstructured":"Kraaij, T. et al. Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. Kidney Int. 94, 139\u2013149 (2018).","journal-title":"Kidney Int."},{"key":"1252_CR105","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.13498","volume":"202","author":"S Moiseev","year":"2020","unstructured":"Moiseev, S. et al. The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis. Clin. Exp. Immunol. 202, 394\u2013402 (2020).","journal-title":"Clin. Exp. Immunol."},{"key":"1252_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-85852-9","volume":"11","author":"V R\u00e9au","year":"2021","unstructured":"R\u00e9au, V. et al. Venous thrombosis and predictors of relapse in eosinophil-related diseases. Sci. Rep. 11, 1\u201310 (2021).","journal-title":"Sci. Rep."},{"key":"1252_CR107","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1172\/JCI116382","volume":"91","author":"A Slungaard","year":"1993","unstructured":"Slungaard, A. et al. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J. Clin. Invest. 91, 1721\u20131730 (1993).","journal-title":"J. Clin. Invest."},{"key":"1252_CR108","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1084\/jem.20161070","volume":"214","author":"S Uderhardt","year":"2017","unstructured":"Uderhardt, S. et al. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. J. Exp. Med. 214, 2121\u20132138 (2017).","journal-title":"J. Exp. Med."},{"key":"1252_CR109","doi-asserted-by":"publisher","first-page":"e874","DOI":"10.1016\/S2665-9913(21)00253-8","volume":"3","author":"F Ciccia","year":"2021","unstructured":"Ciccia, F. et al. New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? Lancet Rheumatol. 3, e874\u2013e885 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1252_CR110","doi-asserted-by":"publisher","first-page":"H1052","DOI":"10.1152\/ajpheart.00024.2017","volume":"312","author":"R Watanabe","year":"2017","unstructured":"Watanabe, R. et al. Immune checkpoint dysfunction in large and medium vessel vasculitis. Am. J. Physiol. Heart Circ. Physiol. 312, H1052\u2013H1059 (2017).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1252_CR111","doi-asserted-by":"publisher","first-page":"eaal3322","DOI":"10.1126\/scitranslmed.aal3322","volume":"9","author":"Z Wen","year":"2017","unstructured":"Wen, Z. et al. The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway. Sci. Transl. Med. 9, eaal3322 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1252_CR112","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1002\/art.34647","volume":"64","author":"M Samson","year":"2012","unstructured":"Samson, M. et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 64, 3788\u20133798 (2012).","journal-title":"Arthritis Rheum."},{"key":"1252_CR113","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/08916934.2015.1027815","volume":"48","author":"T Shirai","year":"2015","unstructured":"Shirai, T. et al. Macrophages in vascular inflammation \u2014 from atherosclerosis to vasculitis. Autoimmunity 48, 139 (2015).","journal-title":"Autoimmunity"},{"key":"1252_CR114","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1161\/CIRCRESAHA.118.313206","volume":"123","author":"R Watanabe","year":"2018","unstructured":"Watanabe, R. et al. MMP (matrix metalloprotease)-9-producing monocytes enable T cells to invade the vessel wall and cause vasculitis. Circ. Res. 123, 700\u2013715 (2018).","journal-title":"Circ. Res."},{"key":"1252_CR115","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2013.161","volume":"9","author":"CM Weyand","year":"2013","unstructured":"Weyand, C. M. & Goronzy, J. J. Immune mechanisms in medium and large-vessel vasculitis. Nat. Rev. Rheumatol. 9, 731\u2013740 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1252_CR116","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1002\/art.22922","volume":"56","author":"C Salvarani","year":"2007","unstructured":"Salvarani, C. et al. PlA1\/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 56, 3502\u20133508 (2007).","journal-title":"Arthritis Rheum."},{"key":"1252_CR117","doi-asserted-by":"publisher","first-page":"435349","DOI":"10.3389\/fimmu.2019.00665","volume":"10","author":"B Tong","year":"2019","unstructured":"Tong, B. et al. Immunopathogenesis of Behcet\u2019s disease. Front. Immunol. 10, 435349 (2019).","journal-title":"Front. Immunol."},{"key":"1252_CR118","doi-asserted-by":"publisher","first-page":"446757","DOI":"10.3389\/fimmu.2019.01085","volume":"10","author":"G Emmi","year":"2019","unstructured":"Emmi, G. et al. Beh\u00e7et\u2019s syndrome as a model of thrombo-inflammation: the role of neutrophils. Front. Immunol. 10, 446757 (2019).","journal-title":"Front. Immunol."},{"key":"1252_CR119","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1136\/annrheumdis-2018-214335","volume":"78","author":"A Le Joncour","year":"2019","unstructured":"Le Joncour, A. et al. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet\u2019s disease. Ann. Rheum. Dis. 78, 1274\u20131282 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1252_CR120","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","volume":"133","author":"M Becatti","year":"2016","unstructured":"Becatti, M. et al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Beh\u00e7et disease. Circulation 133, 302\u2013311 (2016).","journal-title":"Circulation"},{"key":"1252_CR121","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/0003319710382417","volume":"62","author":"N Acikgoz","year":"2011","unstructured":"Acikgoz, N. et al. Elevated oxidative stress markers and its relationship with endothelial dysfunction in Beh\u00e7et disease. Angiology 62, 296\u2013300 (2011).","journal-title":"Angiology"},{"key":"1252_CR122","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1620\/tjem.197.9","volume":"197","author":"K Kose","year":"2002","unstructured":"Kose, K. et al. Lipid peroxidation and erythrocyte antioxidant enzymes in patients with Beh\u00e7et\u2019s disease. Tohoku J. Exp. Med. 197, 9\u201316 (2002).","journal-title":"Tohoku J. Exp. Med."},{"key":"1252_CR123","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2133.2004.06003.x","volume":"151","author":"C Yazici","year":"2004","unstructured":"Yazici, C. et al. Increased advanced oxidation protein products in Beh\u00e7et\u2019s disease: a new activity marker? Br. J. Dermatol. 151, 105\u2013111 (2004).","journal-title":"Br. J. Dermatol."},{"key":"1252_CR124","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1365-2133.2005.06543.x","volume":"153","author":"S Buldanlioglu","year":"2005","unstructured":"Buldanlioglu, S. et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Beh\u00e7et\u2019s disease. Br. J. Dermatol. 153, 526\u2013530 (2005).","journal-title":"Br. J. Dermatol."},{"key":"1252_CR125","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1161\/ATVBAHA.111.242859","volume":"32","author":"TA Fuchs","year":"2012","unstructured":"Fuchs, T. A., Brill, A. & Wagner, D. D. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler. Thromb. Vasc. Biol. 32, 1777\u20131783 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1252_CR126","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1093\/rheumatology\/kez229","volume":"58","author":"E Houben","year":"2019","unstructured":"Houben, E. et al. Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis. Rheumatology 58, 2333\u20132335 (2019).","journal-title":"Rheumatology"},{"key":"1252_CR127","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1046\/j.1523-1755.2003.00718.x","volume":"63","author":"M Choi","year":"2003","unstructured":"Choi, M. et al. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int. 63, 96\u2013106 (2003).","journal-title":"Kidney Int."},{"key":"1252_CR128","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00296-020-04562-z","volume":"40","author":"M Yamaguchi","year":"2020","unstructured":"Yamaguchi, M. et al. Association between statin use and incidence of relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-center retrospective cohort study. Rheumatol. Int. 40, 1291\u20131299 (2020).","journal-title":"Rheumatol. Int."},{"key":"1252_CR129","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/ckj\/sfac009","volume":"15","author":"L Floyd","year":"2022","unstructured":"Floyd, L. et al. Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat? Clin. Kidney J. 15, 618\u2013623 (2022).","journal-title":"Clin. Kidney J."},{"key":"1252_CR130","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1164\/rccm.202308-1426OC","volume":"209","author":"LA Fussner","year":"2024","unstructured":"Fussner, L. A. et al. Alveolar hemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: results of an international randomized controlled trial (PEXIVAS). Am. J. Respir. Crit. Care Med. 209, 1141\u20131151 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1252_CR131","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne, D. R. W. et al. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384, 599\u2013609 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1252_CR132","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","volume":"321","author":"SL Zheng","year":"2019","unstructured":"Zheng, S. L. & Roddick, A. J. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA 321, 277\u2013287 (2019).","journal-title":"JAMA"},{"key":"1252_CR133","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","volume":"126","author":"HU Simon","year":"2010","unstructured":"Simon, H. U. et al. Refining the definition of hypereosinophilic syndrome. J. Allergy Clin. Immunol. 126, 45\u201349 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1252_CR134","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13223-022-00666-2","volume":"18","author":"K Aukstuolis","year":"2022","unstructured":"Aukstuolis, K. et al. Hypereosinophilic syndrome presenting as coagulopathy. Allergy Asthma Clin. Immunol. 18, 25 (2022).","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"1252_CR135","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1177\/1076029609348647","volume":"16","author":"PRJ Ames","year":"2009","unstructured":"Ames, P. R. J. et al. Eosinophilia and thrombophilia in Churg Strauss syndrome: a clinical and pathogenetic overview. Clin. Appl. Thromb. Hemost. 16, 628\u2013636 (2009).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"1252_CR136","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/j.seminhematol.2012.01.002","volume":"49","author":"HU Simon","year":"2012","unstructured":"Simon, H. U. & Klion, A. Therapeutic approaches to patients with hypereosinophilic syndromes. Semin. Hematol. 49, 160\u2013170 (2012).","journal-title":"Semin. Hematol."},{"key":"1252_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-50527-z","volume":"9","author":"L Pan","year":"2019","unstructured":"Pan, L. et al. Takayasu arteritis with dyslipidemia increases risk of aneurysm. Sci. Rep. 9, 1\u20139 (2019).","journal-title":"Sci. Rep."},{"key":"1252_CR138","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/M12-3046","volume":"160","author":"G Tomasson","year":"2014","unstructured":"Tomasson, G. et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann. Intern. Med. 160, 73 (2014).","journal-title":"Ann. Intern. Med."},{"key":"1252_CR139","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/rheumatology\/kev262","volume":"55","author":"N Amiri","year":"2016","unstructured":"Amiri, N. et al. Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study. Rheumatology 55, 33\u201340 (2016).","journal-title":"Rheumatology"},{"key":"1252_CR140","first-page":"737","volume":"29","author":"A Uddhammar","year":"2002","unstructured":"Uddhammar, A. et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J. Rheumatol. 29, 737\u2013742 (2002).","journal-title":"J. Rheumatol."},{"key":"1252_CR141","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1002\/art.22141","volume":"54","author":"MS Lee","year":"2006","unstructured":"Lee, M. S. et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 54, 3306\u20133309 (2006).","journal-title":"Arthritis Rheum."},{"key":"1252_CR142","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/art.20171","volume":"50","author":"G Nesher","year":"2004","unstructured":"Nesher, G. et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 50, 1332\u20131337 (2004).","journal-title":"Arthritis Rheum."},{"key":"1252_CR143","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.autrev.2014.02.006","volume":"13","author":"VM Mart\u00ednez-Taboada","year":"2014","unstructured":"Mart\u00ednez-Taboada, V. M. et al. Effect of antiplatelet\/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun. Rev. 13, 788\u2013794 (2014).","journal-title":"Autoimmun. Rev."},{"key":"1252_CR144","first-page":"CD0104532014","volume":"2014","author":"SP Mollan","year":"2014","unstructured":"Mollan, S. P. et al. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst. Rev. 2014, CD0104532014 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1252_CR145","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich, B. et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 79, 19\u201330 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1252_CR146","doi-asserted-by":"publisher","first-page":"101826","DOI":"10.1016\/j.berh.2023.101826","volume":"37","author":"DP Misra","year":"2023","unstructured":"Misra, D. P. et al. Management of Takayasu arteritis. Best Pract. Res. Clin. Rheumatol. 37, 101826 (2023).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"1252_CR147","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/imm.12902","volume":"154","author":"R Zeiser","year":"2018","unstructured":"Zeiser, R. Immune modulatory effects of statins. Immunology 154, 69\u201375 (2018).","journal-title":"Immunology"},{"key":"1252_CR148","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.semarthrit.2006.10.001","volume":"36","author":"J Narv\u00e1ez","year":"2007","unstructured":"Narv\u00e1ez, J. et al. Statin therapy does not seem to benefit giant cell arteritis. Semin. Arthritis Rheum. 36, 322\u2013327 (2007).","journal-title":"Semin. Arthritis Rheum."},{"key":"1252_CR149","first-page":"232","volume":"76","author":"P Merkel","year":"2014","unstructured":"Merkel, P. et al. Efficacy and safety of upadacitinib in patients with giant cell arteritis (SELECT-GCA): a double-blind, randomized controlled phase 3 trial [abstract]. Arthritis Rheumatol. 76, 232\u2013233 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1252_CR150","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi, G. et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann. Rheum. Dis. 77, 808\u2013818 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1252_CR151","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/art.40531","volume":"70","author":"G Emmi","year":"2018","unstructured":"Emmi, G. et al. Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Beh\u00e7et\u2019s Syndrome: a retrospective study of seventy patients with vascular involvement. Arthritis Rheumatol. 70, 1500\u20131507 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1252_CR152","doi-asserted-by":"publisher","first-page":"109682","DOI":"10.1016\/j.clim.2023.109682","volume":"253","author":"G Hatemi","year":"2023","unstructured":"Hatemi, G. et al. Infliximab for vascular involvement in Beh\u00e7et\u2019s syndrome. Clin. Immunol. 253, 109682 (2023).","journal-title":"Clin. Immunol."},{"key":"1252_CR153","first-page":"EVIDoa2300354","volume":"33","author":"D Hatemi","year":"2024","unstructured":"Saadoun, D. et al. Infliximab versus cyclophosphamide for severe Beh\u00e7et\u2019s syndrome. NEJM Evid. 33, EVIDoa2300354 (2024).","journal-title":"NEJM Evid."},{"key":"1252_CR154","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter, I. et al. The use of interferon \u03b1 in Beh\u00e7et disease: review of the literature. Semin. Arthritis Rheum. 33, 320\u2013335 (2004).","journal-title":"Semin. Arthritis Rheum."},{"key":"1252_CR155","doi-asserted-by":"publisher","first-page":"109298","DOI":"10.1016\/j.clim.2023.109298","volume":"250","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Baricitinib for the treatment of refractory vascular Beh\u00e7et\u2019s disease. Clin. Immunol. 250, 109298 (2023).","journal-title":"Clin. Immunol."},{"key":"1252_CR156","doi-asserted-by":"publisher","first-page":"109241","DOI":"10.1016\/j.clim.2023.109241","volume":"247","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. Baricitinib for the treatment of intestinal Beh\u00e7et\u2019s disease: a pilot study. Clin. Immunol. 247, 109241 (2023).","journal-title":"Clin. Immunol."},{"key":"1252_CR157","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","volume":"79","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. A pilot study of tofacitinib for refractory Beh\u00e7et\u2019s syndrome. Ann. Rheum. Dis. 79, 1517\u20131520 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1252_CR158","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/art.34450","volume":"64","author":"AC Desbois","year":"2012","unstructured":"Desbois, A. C. et al. Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et\u2019s disease. Arthritis Rheum. 64, 2753\u20132760 (2012).","journal-title":"Arthritis Rheum."},{"key":"1252_CR159","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10067-007-0685-z","volume":"27","author":"JK Ahn","year":"2008","unstructured":"Ahn, J. K. et al. Treatment of venous thrombosis associated with Behcet\u2019s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin. Rheumatol. 27, 201\u2013205 (2008).","journal-title":"Clin. Rheumatol."},{"key":"1252_CR160","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/10815589241232368","volume":"72","author":"S Erol","year":"2024","unstructured":"Erol, S. et al. Does anticoagulation in combination with immunosuppressive therapy prevent recurrent thrombosis in Beh\u00e7et\u2019s disease? J. Invest. Med. 72, 387\u2013391 (2024).","journal-title":"J. Invest. Med."},{"key":"1252_CR161","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.surg.2015.11.022","volume":"159","author":"Q Liu","year":"2016","unstructured":"Liu, Q. et al. Outcomes of vascular intervention and use of perioperative medications for nonpulmonary aneurysms in Beh\u00e7et disease. Surgery 159, 1422\u20131429 (2016).","journal-title":"Surgery"},{"key":"1252_CR162","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/152660280301000116","volume":"10","author":"BK Koo","year":"2003","unstructured":"Koo, B. K. et al. Endovascular therapy combined with immunosuppressive treatment for pseudoaneurysms in patients with Beh\u00e7et\u2019s disease. J. Endovasc. Ther. 10, 75\u201380 (2003).","journal-title":"J. Endovasc. Ther."},{"key":"1252_CR163","first-page":"2057","volume":"57","author":"Y Ding","year":"2018","unstructured":"Ding, Y. et al. Tocilizumab in the treatment of severe and\/or refractory vasculo-Beh\u00e7et\u2019s disease: a single-centre experience in China. Rheumatology 57, 2057\u20132059 (2018).","journal-title":"Rheumatology"},{"key":"1252_CR164","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/rheumatology\/keab840","volume":"61","author":"H Zhong","year":"2022","unstructured":"Zhong, H. et al. Efficacy and safety of tocilizumab in Beh\u00e7et\u2019s syndrome with refractory arterial lesions: a single-centre observational cohort study in China. Rheumatology 61, 2923\u20132930 (2022).","journal-title":"Rheumatology"},{"key":"1252_CR165","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1307361","volume":"370","author":"Q Zhou","year":"2014","unstructured":"Zhou, Q. et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N. Engl. J. Med. 370, 911\u2013920 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1252_CR166","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3174\/ajnr.A7019","volume":"42","author":"AF Geraldo","year":"2021","unstructured":"Geraldo, A. F. et al. Widening the neuroimaging features of adenosine deaminase 2 deficiency. Am. J. Neuroradiol. 42, 975\u2013979 (2021).","journal-title":"Am. J. Neuroradiol."},{"key":"1252_CR167","doi-asserted-by":"publisher","first-page":"811473","DOI":"10.3389\/fimmu.2021.811473","volume":"12","author":"KS Barron","year":"2022","unstructured":"Barron, K. S. et al. The spectrum of the deficiency of adenosine deaminase 2: an observational analysis of a 60 patient cohort. Front. Immunol. 12, 811473 (2022).","journal-title":"Front. Immunol."},{"key":"1252_CR168","first-page":"111","volume":"48","author":"M Elbracht","year":"2017","unstructured":"Elbracht, M. et al. Stroke as initial manifestation of adenosine deaminase 2 deficiency. Neuropediatrics 48, 111\u2013114 (2017).","journal-title":"Neuropediatrics"},{"key":"1252_CR169","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16043","volume":"31","author":"MA Verschoof","year":"2024","unstructured":"Verschoof, M. A. et al. Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study. Eur. J. Neurol. 31, e16043 (2024).","journal-title":"Eur. J. Neurol."},{"key":"1252_CR170","doi-asserted-by":"publisher","first-page":"935957","DOI":"10.3389\/fimmu.2022.935957","volume":"13","author":"S Signa","year":"2022","unstructured":"Signa, S. et al. Adenosine deaminase 2 deficiency (DADA2): a crosstalk between innate and adaptive immunity. Front. Immunol. 13, 935957 (2022).","journal-title":"Front. Immunol."},{"key":"1252_CR171","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.revmed.2017.11.006","volume":"39","author":"A Fayand","year":"2018","unstructured":"Fayand, A. et al. [Multiple facets of ADA2 deficiency: vasculitis, auto-inflammatory disease and immunodeficiency: a literature review of 135 cases from literature]. Rev. Med. Interne 39, 297\u2013306 (2018).","journal-title":"Rev. Med. Interne"},{"key":"1252_CR172","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.neurad.2018.05.002","volume":"46","author":"E Bulut","year":"2019","unstructured":"Bulut, E. et al. Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. J. Neuroradiol. 46, 193\u2013198 (2019).","journal-title":"J. Neuroradiol."},{"key":"1252_CR173","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1546-0096-12-44","volume":"12","author":"A Belot","year":"2014","unstructured":"Belot, A. et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr. Rheumatol. Online J. 12, 44 (2014).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1252_CR174","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood.2018892752","volume":"134","author":"C Carmona-Rivera","year":"2019","unstructured":"Carmona-Rivera, C. et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. Blood 134, 395\u2013406 (2019).","journal-title":"Blood"},{"key":"1252_CR175","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10875-018-0525-8","volume":"38","author":"I Meyts","year":"2018","unstructured":"Meyts, I. & Aksentijevich, I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J. Clin. Immunol. 38, 569\u2013578 (2018).","journal-title":"J. Clin. Immunol."},{"key":"1252_CR176","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1093\/rheumatology\/keaa837","volume":"60","author":"S Cooray","year":"2021","unstructured":"Cooray, S. et al. Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). Rheumatology 60, 4373\u20134378 (2021).","journal-title":"Rheumatology"},{"key":"1252_CR177","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1056\/NEJMc1801927","volume":"380","author":"AK Ombrello","year":"2019","unstructured":"Ombrello, A. K. et al. Treatment strategies for deficiency of adenosine deaminase 2. N. Engl. J. Med. 380, 1582\u20131584 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1252_CR178","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.15894","volume":"6","author":"PY Lee","year":"2023","unstructured":"Lee, P. Y. et al. Evaluation and management of deficiency of adenosine deaminase 2: an international consensus statement. JAMA Netw. Open\u00a06, e2315894 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1252_CR179","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck, D. B. et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N. Engl. J. Med. 383, 2628\u20132638 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1252_CR180","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002255","volume":"8","author":"MY Khitri","year":"2022","unstructured":"Khitri, M. Y. et al. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open\u00a08, e002255 (2022).","journal-title":"RMD Open"},{"key":"1252_CR181","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1182\/blood.2023022329","volume":"143","author":"Y Kusne","year":"2024","unstructured":"Kusne, Y. et al. Venous and arterial thrombosis in patients with VEXAS syndrome. Blood 143, 2190\u20132200 (2024).","journal-title":"Blood"},{"key":"1252_CR182","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","volume":"5","author":"IE Obiorah","year":"2021","unstructured":"Obiorah, I. E. et al. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv. 5, 3203\u20133215 (2021).","journal-title":"Blood Adv."},{"key":"1252_CR183","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle, S. et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large\u2010scale analysis of a multicentre case series of 116 French patients. Br. J. Dermatol. 186, 564\u2013574 (2022).","journal-title":"Br. J. Dermatol."},{"key":"1252_CR184","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s11239-021-02608-y","volume":"53","author":"TM Oo","year":"2022","unstructured":"Oo, T. M. et al. Thrombosis in VEXAS syndrome. J. Thromb. Thrombolysis 53, 965\u2013970 (2022).","journal-title":"J. Thromb. Thrombolysis"},{"key":"1252_CR185","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1055\/s-0035-1556727","volume":"41","author":"NV Butta","year":"2015","unstructured":"Butta, N. V. et al. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Beh\u00e7et disease. Semin. Thromb. Hemost. 41, 621\u2013628 (2015).","journal-title":"Semin. Thromb. Hemost."},{"key":"1252_CR186","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/jth.15858","volume":"20","author":"L Khider","year":"2022","unstructured":"Khider, L. et al. Systematic search for the UBA1 mutation in men after a first episode of venous thromboembolism: a monocentric study. J. Thromb. Haemost. 20, 2697\u20132699 (2022).","journal-title":"J. Thromb. Haemost."},{"key":"1252_CR187","first-page":"3591","volume":"137","author":"PC Grayson","year":"2021","unstructured":"Grayson, P. C., Patel, B. A. & Young, N. S. VEXAS syndrome. Blood 137, 3591\u20133594 (2021).","journal-title":"Blood"},{"key":"1252_CR188","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/15353702231165030","volume":"248","author":"S Bindoli","year":"2023","unstructured":"Bindoli, S. et al. JAK inhibitors for the treatment of VEXAS syndrome. Exp. Biol. Med. 248, 394\u2013398 (2023).","journal-title":"Exp. Biol. Med."},{"key":"1252_CR189","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ajh.27156","volume":"99","author":"MJ Koster","year":"2024","unstructured":"Koster, M. J. et al. VEXAS syndrome: clinical, hematologic features and a practical approach to diagnosis and management. Am. J. Hematol. 99, 284\u2013299 (2024).","journal-title":"Am. J. Hematol."},{"key":"1252_CR190","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jaut.2018.09.004","volume":"96","author":"M Mourguet","year":"2019","unstructured":"Mourguet, M. et al. Increased ischemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis. J. Autoimmun. 96, 134\u2013141 (2019).","journal-title":"J. Autoimmun."},{"key":"1252_CR191","first-page":"477","volume":"34","author":"B Al-Ani","year":"2013","unstructured":"Al-Ani, B. Simvastatin inhibits neutrophil degranulation induced by anti-neutrophil cytoplasm auto-antibodies and N-formyl-methionine-leucine-phenylalanine (fMLP) peptide. Saudi Med. J. 34, 477\u2013483 (2013).","journal-title":"Saudi Med. J."},{"key":"1252_CR192","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1111\/j.1756-185X.2010.01481.x","volume":"13","author":"D Sen","year":"2010","unstructured":"Sen, D., Rosenstein E. D., Kramer N. ANCA-positive vasculitis associated with simvastatin\/ezetimibe: expanding the spectrum of statin-induced autoimmunity? Int. J. Rheum. Dis. 13, e29\u2013e31 (2010).","journal-title":"Int. J. Rheum. Dis."},{"key":"1252_CR193","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10067-008-1020-z","volume":"27","author":"M Haroon","year":"2008","unstructured":"Haroon, M. & Devlin, J. A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin. Rheumatol. 27, 75\u201377 (2008).","journal-title":"Clin. Rheumatol."},{"key":"1252_CR194","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejim.2021.11.001","volume":"95","author":"Y Yamashita","year":"2022","unstructured":"Yamashita, Y., Morimoto, T. & Kimura, T. Optimal duration of anticoagulation therapy for venous thromboembolism in autoimmune diseases. Eur. J. Intern. Med. 95, 102\u2013103 (2022).","journal-title":"Eur. J. Intern. Med."},{"key":"1252_CR195","doi-asserted-by":"publisher","first-page":"14404","DOI":"10.1038\/s41598-021-93416-0","volume":"11","author":"C Laurent","year":"2021","unstructured":"Laurent, C. et al. Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. Sci. Rep. 11, 14404 (2021).","journal-title":"Sci. Rep."},{"key":"1252_CR196","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijcard.2019.02.046","volume":"287","author":"OC Kwon","year":"2019","unstructured":"Kwon, O. C. et al. Statins reduce relapse rate in Takayasu arteritis. Int. J. Cardiol. 287, 111\u2013115 (2019).","journal-title":"Int. J. Cardiol."},{"key":"1252_CR197","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijcard.2019.04.024","volume":"287","author":"F Salvo","year":"2019","unstructured":"Salvo, F. & Franchini, S. Statin therapy for Takayasu arteritis. Int. J. Cardiol. 287, 118\u2013119 (2019).","journal-title":"Int. J. Cardiol."},{"key":"1252_CR198","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.1540-8175.2010.01180.x","volume":"27","author":"MT Inanc","year":"2010","unstructured":"Inanc, M. T. et al. Effects of atorvastatin and lisinopril on endothelial dysfunction in patients with Beh\u00e7et\u2019s disease. Echocardiography 27, 997\u20131003 (2010).","journal-title":"Echocardiography"},{"key":"1252_CR199","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"GC Jennette","year":"2013","unstructured":"Jennette, G. C. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65, 1\u201311 (2013).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01252-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01252-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01252-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T07:02:56Z","timestamp":1760684576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01252-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":199,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1038\/s41584-025-01252-7","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"3 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}